Biocryst Pharmaceuticals (BCRX) Other Accumulated Expenses (2013 - 2021)

Biocryst Pharmaceuticals has reported Other Accumulated Expenses for 9 years, with the latest figure at $3.7 million in Q4 2021.

• For the quarter ending Q4 2021, Other Accumulated Expenses fell 24.85% year-over-year to $3.7 million; the trailing twelve-month figure through Dec 2021 stood at $3.7 million (down 24.85% YoY), and the FY2021 full-year result was $3.7 million, down 24.85% from the prior year.
• Other Accumulated Expenses for Q4 2021 stood at $3.7 million, down from $4.9 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $4.9 million in Q4 2020, with the low at $1.8 million in Q4 2018.
• Historically, Other Accumulated Expenses has averaged $3.2 million across 5 years, with a median of $3.5 million in 2019.
• Annual changes were most pronounced in 2019 — Other Accumulated Expenses surged 86.54% — and 2021, when it fell 24.85%.
• Biocryst Pharmaceuticals' Other Accumulated Expenses stood at $2.2 million in 2017, then fell by 17.19% to $1.8 million in 2018, then surged by 86.54% to $3.5 million in 2019, then soared by 41.81% to $4.9 million in 2020, then slipped by 24.85% to $3.7 million in 2021.
• The last three Other Accumulated Expenses figures came in at $3.7 million (Q4 2021), $4.9 million (Q4 2020), and $3.5 million (Q4 2019), per Business Quant data.